Overview of Cattle Diseases Listed Under Category C, D or E in the Animal Health Law for Which Control Programmes Are in Place Within Europe.
Europe
SOUND control
cattle
control programmes
disease control
output-based standards
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
03
2021
accepted:
01
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
epublish
Résumé
The COST action "Standardising output-based surveillance to control non-regulated diseases of cattle in the European Union (SOUND control)," aims to harmonise the results of surveillance and control programmes (CPs) for non-EU regulated cattle diseases to facilitate safe trade and improve overall control of cattle infectious diseases. In this paper we aimed to provide an overview on the diversity of control for these diseases in Europe. A non-EU regulated cattle disease was defined as an infectious disease of cattle with no or limited control at EU level, which is not included in the European Union Animal health law Categories A or B under Commission Implementing Regulation (EU) 2020/2002. A CP was defined as surveillance and/or intervention strategies designed to lower the incidence, prevalence, mortality or prove freedom from a specific disease in a region or country. Passive surveillance, and active surveillance of breeding bulls under Council Directive 88/407/EEC were not considered as CPs. A questionnaire was designed to obtain country-specific information about CPs for each disease. Animal health experts from 33 European countries completed the questionnaire. Overall, there are 23 diseases for which a CP exists in one or more of the countries studied. The diseases for which CPs exist in the highest number of countries are enzootic bovine leukosis, bluetongue, infectious bovine rhinotracheitis, bovine viral diarrhoea and anthrax (CPs reported by between 16 and 31 countries). Every participating country has on average, 6 CPs (min-max: 1-13) in place. Most programmes are implemented at a national level (86%) and are applied to both dairy and non-dairy cattle (75%). Approximately one-third of the CPs are voluntary, and the funding structure is divided between government and private resources. Countries that have eradicated diseases like enzootic bovine leukosis, bluetongue, infectious bovine rhinotracheitis and bovine viral diarrhoea have implemented CPs for other diseases to further improve the health status of cattle in their country. The control of non-EU regulated cattle diseases is very heterogenous in Europe. Therefore, the standardising of the outputs of these programmes to enable comparison represents a challenge.
Identifiants
pubmed: 34395571
doi: 10.3389/fvets.2021.688078
pmc: PMC8361752
doi:
Types de publication
Journal Article
Langues
eng
Pagination
688078Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Hodnik, Acinger-Rogić, Alishani, Autio, Balseiro, Berezowski, Carmo, Chaligiannis, Conrady, Costa, Cvetkovikj, Davidov, Dispas, Djadjovski, Duarte, Faverjon, Fourichon, Frössling, Gerilovych, Gethmann, Gomes, Graham, Guelbenzu, Gunn, Henry, Hopp, Houe, Irimia, Ježek, Juste, Kalaitzakis, Kaler, Kaplan, Kostoulas, Kovalenko, Kneževič, Knific, Koleci, Madouasse, Malakauskas, Mandelik, Meletis, Mincu, Mõtus, Muñoz-Gómez, Niculae, Nikitović, Ocepek, Tangen-Opsal, Ózsvári, Papadopoulos, Papadopoulos, Pelkonen, Polak, Pozzato, Rapaliuté, Ribbens, Niza-Ribeiro, Roch, Rosenbaum Nielsen, Saez, Nielsen, van Schaik, Schwan, Sekovska, Starič, Strain, Šatran, Šerić-Haračić, Tamminen, Thulke, Toplak, Tuunainen, Verner, Vilček, Yildiz and Santman-Berends.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Dairy Sci. 2020 May;103(5):4654-4671
pubmed: 32147269
BMC Vet Res. 2019 Jun 13;15(1):198
pubmed: 31196162
EFSA J. 2017 Aug 04;15(8):e04952
pubmed: 32625618
EFSA J. 2017 Oct 12;15(10):e04990
pubmed: 32625287
Prev Vet Med. 2017 Apr 1;139(Pt B):105-114
pubmed: 28122659
Prev Vet Med. 2009 Aug 1;90(3-4):254-67
pubmed: 19464742
EFSA J. 2017 Jul 28;15(7):e04958
pubmed: 32625603
EFSA J. 2017 Jul 28;15(7):e04960
pubmed: 32625604
EFSA J. 2017 Oct 12;15(10):e04992
pubmed: 32625289
EFSA J. 2017 Aug 04;15(8):e04956
pubmed: 32625622
EFSA J. 2017 Oct 04;15(10):e04995
pubmed: 32625292
Biol Rev Camb Philos Soc. 2018 Nov;93(4):1813-1831
pubmed: 29732670
EFSA J. 2017 Aug 04;15(8):e04957
pubmed: 32625623
Prev Vet Med. 2020 Oct;183:105130
pubmed: 32920493
EFSA J. 2017 Jul 28;15(7):e04947
pubmed: 32625599
EFSA J. 2017 Jul 21;15(7):e04892
pubmed: 32625557